INCY Incyte Corporation featured news, full reports, and detailed charts
Incyte Corporation (INCY) Wrap Up:
This report contains forward-looking statements that involve risks and uncertainties. These statements relate to future periods, future events or our future operating or financial plans or performance. These statements can often be identified by the use of forward-looking terminology such as “expects,” “believes,” “intends,” “anticipates,” “estimates,” “plans,” “may,” or “will,” or the negative of these terms, and other similar expressions. These forward-looking statements include statements as to the discovery, development, formulation, manufacturing and commercialization of our compounds and our product candidates; the increase in our drug discovery and development efforts; the expected timing, progress and other information regarding our preclinical testing and clinical trials; conducting clinical trials internally, with collaborators, or with contract research organizations; our collaboration and strategic alliance efforts; anticipated benefits and disadvantages of ente ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2005%2f03%2f11%2f0001193125-05-047638.html#FIS_BUSINESS"Incyte Corporation (INCY:NASDAQ)
Snapshot of Incyte Corporation (INCY)
|
OPEN
$7.61
|
PREVIOUS CLOSE
$7.72
|
|
|
DAY HIGH
$7.80
|
DAY LOW
$7.41
|
|
|
52 WEEK HIGH
11/17/09 - $8.32
|
52 WEEK LOW
11/21/08 - $1.85
|
|
|
MARKET CAP
895.0M
|
AVERAGE VOLUME 3 mo
2.8M
|
|
|
DILUTED EPS TTM
$-1.76
|
SHARES OUTSTANDING
118.5M
|
|
|
INCY Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
INCY Top Compensated Officers
Executives, Board Directors
Key developments for Incyte Corporation (INCY)
Incyte Corporation reported consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company's total revenues were $939,000 against $1,061,000 a year ago. Loss from operations was $31,563,000 against $39,793,000 a year ago. Net loss was $43,357,000 or $0.44 per basic and diluted share against $44,794,000 or $0.48 per basic and diluted share a year ago. For the nine months, the company's total revenues were $2,399,000 against $2,981,000 a year ago. Loss from operations was $98,547,000 against $116,622,000 a year ago. Net loss was $123,428,000 or $1.26 per basic and diluted share against $130,515,000 or $1.50 per basic and diluted share a year ago.
Incyte Corporation expected to Report Fiscal Year 2009 Results on February 15, 2010. This event was calculated by Capital IQ (Created on November 5, 2009).
Incyte Corporation announced that it will propose to the shareholders at its EGM, to be held on November 24, 2009, for the their approval to an amendment to its Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance from 200,000,000 shares to 400,000,000 shares.
INCY Competitors
| Company | Last | Change |
| ARIAD Pharmaceuticals Inc | $2.16 USD | -0.03 |
| ChemGenex Pharmaceuticals Ltd | A$0.93 AUD | -0.04 |
| Idenix Pharmaceuticals Inc | $1.84 USD | +0.01 |
| Panacos Pharmaceuticals Inc | $0.02 USD | +0.001 |
| Pharmasset Inc | $19.66 USD | +0.06 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | INCY | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 221.8x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 8.8x |
|
|
INCY |
||
INCY transactions
| Type Date |
Target |
|
Private Placement
September 22, 2009 |
-- |